Nathalie LeVasseur

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3631742/publications.pdf

Version: 2024-02-01

21 213 7 14 papers citations h-index g-index

22 22 301 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials. Cancer Treatment Reviews, 2016, 50, 183-193.	3.4	39
2	Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review. Breast Cancer Research and Treatment, 2018, 171, 607-620.	1.1	37
3	Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis. Journal of Cancer Research and Clinical Oncology, 2020, 146, 529-536.	1.2	37
4	Optimizing Vascular Access for Patients Receiving Intravenous Systemic Therapy for Early-Stage Breast Cancer—A Survey of Oncology Nurses and Physicians. Current Oncology, 2018, 25, 298-304.	0.9	24
5	Perceptions of Vascular Access for Intravenous Systemic Therapy and Risk Factors for Lymphedema in Early-Stage Breast Cancer—A Patient Survey. Current Oncology, 2018, 25, 305-310.	0.9	18
6	Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database. Clinical Breast Cancer, 2019, 19, e683-e689.	1.1	12
7	Optimising weight-loss interventions in cancer patients—A systematic review and network meta-analysis. PLoS ONE, 2021, 16, e0245794.	1.1	11
8	Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility Study. Clinical Breast Cancer, 2022, 22, e74-e79.	1.1	8
9	Effects of High Anxiety Scores on Surgical and Overall Treatment Plan in Patients with Breast Cancer Treated with Neoadjuvant Therapy. Oncologist, 2020, 25, 212-217.	1.9	7
10	Neoadjuvant endocrine therapy and window of opportunity trials: new standards in the treatment of breast cancer?. Minerva Chirurgica, 2015, 70, 181-93.	0.8	6
11	Clinical utility of MRI in the neoadjuvant management of early-stage breast cancer. Breast Cancer Research and Treatment, 0, , .	1.1	4
12	Examining social media peer support and improving psychosocial outcomes for young women with breast cancer Journal of Clinical Oncology, 2021, 39, 162-162.	0.8	3
13	Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?. British Journal of Cancer, 2019, 121, 1-2.	2.9	2
14	Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?. British Journal of Cancer, 2017, 117, 157-158.	2.9	1
15	Unnecessary Variation in Practice: How to Improve Cancer Care through Pragmatic Trials. Current Oncology, 2018, 25, 263-264.	0.9	1
16	Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients. Breast Cancer Research and Treatment, 2021, 187, 167-176.	1.1	1
17	Comparing outcomes of neoadjuvant endocrine therapy versus chemotherapy in ER-positive breast cancer: Results from a prospective institutional database Journal of Clinical Oncology, 2017, 35, 581-581.	0.8	1
18	Whole genome sequencing in metastatic breast cancer: Lessons learned from the BC Cancer personalized oncogenomics program Journal of Clinical Oncology, 2018, 36, 12065-12065.	0.8	1

#	Article	IF	CITATIONS
19	Can We Hang Our Hats on One Percent?. Oncologist, 2018, 23, 642-644.	1.9	0
20	Weight control strategies in breast cancer patients: A systematic review Journal of Clinical Oncology, 2016, 34, 179-179.	0.8	0
21	Optimal weight control strategies in cancer patients: A systematic review Journal of Clinical Oncology, 2016, 34, 10109-10109.	0.8	0